RESULTS Act

H.R. 1805, Assistance for Rural Community Hospitals (ARCH) Act, all provisions; S. 1261 / H.R. 4206, CONNECT for Health Act of 2025, all provisions; H.R. 2191, Physician Led and Rural Access to Quality Care Act, all provisions; S. 335, Rural Hospital Support Act, all provisions; S.1816 / H.R.3514, Improving Seniors Timely Access to Care Act, all provisions; S. 502, Rural Hospital Closure Relief Act, all provisions; S. 2439 / H.R. 4731, Resident Physician Shortage Reduction Act of 2025, all provisions; H.R. 4002, Patient Access to Higher Quality Health Care Act, all provisions; H.R. 5454/S. 2879, the Medicare Advantage Prompt Pay Act, all provisions; H.R. 6240, Rural Hospital Closure Relief Act of 2025, all provisions; H.R. 8375/ S. 4384, Medicare Advantage Improvement Act, all provisions; H.R. 8967 / S. 4460, Rural Community Hospital Demonstration Program Reauthorization, all provisions; H.R. 9468, Saving Today's Acute Care Resources (STAR) Act, all provisions; H.R. 8891, Rural Maternity Options for Medial Support (Rural MOMS) Act, all provisions; H.R. 3108 / S. 1535, Rural Patient Monitoring Access Act (RPM Access Act), all provisions; S. 2761 / H.R. 5269, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act , all provisions; H.R. 5142, The Home Health Stabilization Act, all provisions; H.R. 8261, Chronic Care Management Improvement Act, all provisions; DRAFT, HCA Mission Act, all provisions; H.R. 9642, Medicare Access to Rural Anesthesiology Act, all provisions; H.R. 9644, Medicare Advantage MLR Transparency Act, all provisions; H.R. 9693, Patients First Act of 2026, all provisions; H.R. 8163, Provider Reimbursement Stability Act of 2026, all provisions; H.R. 8622, Medicare Physician Data-driven Performance Payment system, all provisions; DRAFT, Medicare Provider Reimbursement Step to Stabilization Act of 2026, Issues pertaining to physician fee schedule reforms; H.R.10666, Frontier Community Health Integration Project Extension Act, all provisions; H.R. 1775, Second Chances for Rural Hospitals Act, all provisions; Centers for Medicare & Medicaid Services (CMS), Issues regarding proposed rule on Medicaid managed care state-directed payments and Medicaid fee-for-service targeted practitioner payments; Centers for Medicare & Medicaid Services (CMS), Issues pertaining to funding from the Rural Health Transformation Program and how it is distributed to hospitals; Centers for Medicare & Medicaid Services (CMS), Issues pertaining to the physician fee schedule and updates for the CY2027; Centers for Medicare & Medicaid Services (CMS), "Comments pertaining to the proposed rule regarding the indirect hold harmless threshold of healthcare-related taxes. "; Centers for Medicare & Medicaid Services (CMS), Issues pertaining to interim final rule on community engagement requirements for certain Medicaid beneficiaries; Centers for Medicare & Medicaid Services (CMS), Issues pertaining to the hospital outpatient prospective payment system and ambulatory surgical center payment system proposed rule for calendar year 2027; Centers for Medicare & Medicaid Services (CMS), Issues pertaining to the calendar year 2027 home health prospective payment system proposed rule; Centers for Medicare & Medicaid Services (CMS), Issues pertaining to the CMS proposed rule implementing and codifying the Medicare Drug Benefit Program under the Inflation Reduction Act of 2022; Centers for Medicare & Medicaid Services (CMS), Issues pertaining to Essential Health Benefits framework and Affordable Care Act requirements; Medicaid Program, Issues pertaining to Medicaid program and how states finance programs, reimburse providers, and determine beneficiary eligibility, and implementation and mitigation of H.R. 1 provisions related to state directed payments, provider taxes and community engagement requirements; Site Neutral Payments, Issues related to site neutral payment cuts and facility fees; Rural Hospitals, Issues pertaining to the sustainability of MDHS, CAHs, SCHs, REH's, implementation of Rural Health Transformation Program, rural reclassification policy; Physician Payments, Issues pertaining to alternative payment models, mental health of workforce, physician reimbursement cuts, Medicare Access & CHIP Reauthorization (MACRA) Reforms; Health Plan Accountability, Issues specific to prior authorization, patient access to care, adequate provider networks, inappropriate denials, reducing account receivables, prompt pay and cost-based reimbursement for critical access hospitals under Medicare Advantage, Wasteful and Inappropriate Services Reduction (WISeR) model, transparency in plan denial signatures, inappropriate downcoding, reducing administrative burdens; Provider Reimbursements, Issues related to provider reimbursement, site neutral payment cuts, Medicare/Medicaid program funding, facility fees; Post Acute Care, Issues pertaining to expanding patients' access to crucial services provided by long-term care hospitals, inpatient rehabilitation facilities, skilled nursing facilities, hospital at home, and home health agencies; Expiring Health Care Programs, Issues pertaining to expiring health care programs such as GPCI, Physician reimbursement, Medicare Dependent Hospital Program, and Low-Volume Adjustment program.

Client expense: $3,840,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Issues related to coverage of telehealth services Issues related to Medicare coverage for digital health technologies - S. 1399/H.R. 6197 Issues related to S. 1717/H.R. 5343 Ensuring Patient Access to Critical Breakthrough Products Act Issues related to S. 2761/H.R. 5269 Lab Payments and Results Act Issues related to Medicare coverage of FDA's breakthrough devices Issues related to coverage of diabetes devices and supplies Issues related to Home Health Rule

Client expense: $1,080,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office

Policies, rules, and regulations related to clinical laboratories and Medicare coverage policies. H.R.5269 - Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare payments for lab tests. S.2761 - RESULTS Act - Issues related to Medicare payments for lab tests.

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H. R. 4709 - Newborn Screening Saves Lives Act of 2025 - Support for advancing 21st century genetic screenings protocols for newborns and their families. Issues related to access and affordability for pediatric genetic tests for children and families nationwide. H.R. 5269 - RESULTS Act - issues related to Medicare payments for lab tests. S. 2761 - RESULTS Act - issues related to Medicare payments for lab tests.

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to drugs of abuse testing; RESULTS Act (H.R.5269/S. 2761)

Client expense: Not reported · Firm income: $30,000

Government targets: Centers For Medicare and Medicaid Services (CMS), Health & Human Services, Dept of (HHS), Substance Abuse & Mental Health Services Administration (SAMHSA)

Issues related to drugs of abuse testing; RESULTS Act (H.R.5269/S. 2761)

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, H.R. 9393, the Lower Costs, More Transparency Act, and H.R. 9645, the Health Care Price Certainty for All Americans Act, provisions relating to lab test price transparency; Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.

Client expense: Not reported · Firm income: $110,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to diagnostic testing, Oncology and the Reforming and Enhancing Sustainable Updates to Laboratory Services (the RESULTS Act, S.2761/H.R. 5269). S.1399/H.R.6197, the Health Tech Investment Act S.3287/H.R.6130, Alzheimer's Screening and Prevention (ASAP) Act

Client expense: $310,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R.5269/2761 - RESULTS Act Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing a transitional coverage period, including H.R. 5343/S. 1717- Ensuring Patient Access to Critical Breakthrough Products Act of 2025.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues surrounding laboratory reimbursement Issues surrounding CLIA Histocompatibility laboratory director requirements (S. 2761 / H.R. 5269) Reforming to Efficiently and Safely Utilize Laboratory Services Act (H.R.8890) Enhancing CLIA Act of 2026

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues regarding prevention of antimicrobial resistance and incentives for development of new antibiotics. Reform of Medicare clinical laboratory payment per Section 216 of Protecting Access to Medicare Act, Pub. L. No. 113-93, and H.R.5269/S.2761, The Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act. Reforming technical certification of in vitro diagnostic tests.

Client expense: Not reported · Firm income: $70,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues regarding prevention of antimicrobial resistance and incentives for development of new antibiotics. Reform of Medicare clinical laboratory payment per Section 216 of Protecting Access to Medicare Act, Pub. L. No. 113-93, and H.R.5269/S.2761, The Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act. Reforming technical certification of in vitro diagnostic tests.

Client expense: Not reported · Firm income: $70,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues regarding prevention of antimicrobial resistance and incentives for development of new antibiotics. Reform of Medicare clinical laboratory payment per Section 216 of Protecting Access to Medicare Act, Pub. L. No. 113-93, and H.R.5269/S.2761, The Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act. Support for H.R.3164/S.2426, Ensuring Community Access to Pharmacist Services Act.

Client expense: Not reported · Firm income: $70,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Medicare contractor issues related to coverage and reimbursement for drugs, including accreditation issues. Clinical Laboratory Fee Schedule and Physician Fee Schedule Proposed Medicare Rules. S. 2761/H.R. 5269, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act of 2025 (The RESULTS Act).

Client expense: Not reported · Firm income: $30,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE

Payment and regulation of clinical laboratory tests. H.R.5269/S.2761, The Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act.

Client expense: Not reported · Firm income: $140,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Antimicrobial resistance; advanced molecular detection; national wastewater surveillance system (S.4048 - PREDICT Act); PAMA reform: RESULTS Act (H.R. 5269 S.2761); PASTEUR Act (H.R. 7352 and S. 4875); SUPER BUGS Act (H.R. 7879), and Stop Superbugs Act (S.5237).

Client expense: $50,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

One Big Beautiful Bill Act, P.L.119-21. Advocate to protect cancer patients in implementation of changes to Medicaid under the law. Lung Cancer Screening and Prevention Act, H.R. 140. To amend title XVIII of the Social Security Act to authorize the coverage of additional lung cancer screening tests under the Medicare program. Accelerating Kids Access to Care Act, P.L. 119-75. Legislation that alleviates these burdens for families and providers by facilitating coordination across state lines and clarifying the process by which state Medicaid programs can cover specialized treatment regardless of where the child lives and where their care is received. Ensuring Access to Essential Providers Act, S.2793. Bill would require Medicare Advantage plans to cover items and services furnished by certain essential community providers. Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, H.R. 5269, S. 2761. Bill would address Medicare reimbursement of laboratory services. Access to Genetic Counselor Services Act, H.R.6280, S.3607. Bill would expand coverage of genetic counseling services under Medicare. Lung Cancer Screening and Prevention Act of 2025, H.R. 1406. This bill authorizes Medicare coverage of additional types of lung cancer screening tests that are approved by the FDA, regardless of whether they are recommended by the United States Preventive Services Task Force (USPSTF). Increasing Access to Lung Cancer Screening Act, H.R.6178, S.4566. This legislation provides coverage without cost-sharing for lung cancer screening and tobacco cessation to those on Medicaid and codifies existing lung cancer screening requirements and eliminates prior authorization for those on Medicare and private insurance.

Client expense: $1,790,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Clinical Trial Modernization Act, H.R. 3521, S. 4440. Increase access to clinical trials for all persons with cancer to participate by reducing barriers to enrollment, including support for ancillary (non-medical) costs. Harley Jacobsen Clinical Trial Participant Income Exemption Act, S.5127, H.R. 4184. Legislation to amend the Internal Revenue Code of 1986 to exclude from gross income certain compensation to clinical trial participants. To amend the Internal Revenue Code of 1986 to exclude from gross income certain compensation to clinical trial participants, and for other purposes, H.R. 4184. Legislation to amend the Internal Revenue Code of 1986 to exclude from gross income certain compensation to clinical trial participants. Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, H.R. 5269, S. 2761. Bill would address Medicare reimbursement of laboratory services. Asal Sayas National Strategy on Young Adult Cancers Act, S. 4717: Directs the NIH to develop a comprehensive national strategy to address the alarming rise of cancers in adults ages 18 to 49. American Cures Act, S. 4494. This bill would permanently fund several federal agencies and programs that perform biomedical research. Knock Out Cancer Act (H.R. 3873, or KO Cancer Act). The will would boost National Cancer Institute funding by 25% annually for FY2026-2030 to match cancers mortality toll and direct a report on drug shortages.

Client expense: $1,790,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

P.L.119-21 - One Big Beautiful Bill Act H.R.1 and Senate-Passed Amendment to H.R.1 Fiscal Year 2025 Budget Reconciliation H.Con.Res.14 Fiscal Year 2026 Budget Reconciliation Fiscal Year 2027 Budget Reconciliation Issue: Educate Congress on potential financial implications of Medicare and Medicaid cuts and entitlement reform on academic health systems and teaching hospitals, medical schools, and faculty practices and the impact on patients access to care and the nations health. Support preservation of non-profit tax status of AAMC member institutions. Oppose reduction in Medicare hospital outpatient department reimbursement and site-neutral expansion to excepted off-campus provider-based departments (PBDs). Oppose creation of National Provider Number/unique identifier for off-campus hospital outpatient departments. Oppose Medicare hospital and provider cuts, including Medicare graduate medical education (GME) reforms, reduction or elimination of bad debt reimbursement, reforming Medicare disproportionate share hospital payments and uncompensated care, prevention of rural reclassification, and reductions in wage index. Oppose cuts to federal Medicaid funding, including reductions to the federal medical assistance percentage (FMAP), changes to provider taxes and state-directed payments, and the implementation of per-capita caps or block grants. Oppose policies that restrict access to coverage and care for the Medicaid population, such as work/community engagement requirements, more frequent eligibility redeterminations, and additional cost-sharing. Oppose limits on Affordable Care Act (ACA) premium tax credit eligibility and restrictions on eligibility for and enrollment in ACA Marketplace plans. Oppose reducing Medicare reimbursement for 340B-acquired drugs. Issue: Oppose restrictions on federal Medicaid funding for certain disfavored services Issue: Educate lawmakers on the need to delay, undo, or revise pending new restrictions on to provider taxes and state-directed payments, along with implement strategies to mitigate coverage losses due to the One Big Beautiful Bill Acts (OBBBA) work requirements and more frequent eligibility redeterminations for the Affordable Care Act (ACA) expansion population. Issue: Educate lawmakers on the importance of academic health systems, teaching hospitals, and physician practice eligibility for Rural Health Transformation Program (RHTP), support increased funding for RHTP. Issue: Educate Congress and policymakers on the financial challenges facing academic health systems and teaching hospitals, medical schools, and faculty practices and the impact on patients access to care and the nations health. H.R.7409 - Defend Rural Health Act Issue: Oppose efforts to repeal or curtail the ability of urban hospitals to become rural referral centers or reclassify for the purposes of their wage index. Issue: Educate Congress and policymakers on the role academic health systems, teaching hospitals, medical schools, and faculty practices play in caring for rural patients and communities, training providers to practice in rural communities, and ensuring access to critical health care services not otherwise available. Issue: Educate Congress on impact of Statutory Pay-As-You-Go Act Medicare sequester H.R.1835 - Breaking the Gridlock Act S.3385 - Lower Health Care Costs Act S.3386 - Health Care Freedom for Patients Act of 2025 Issue: Support clean extension of Affordable Care Act (ACA) enhanced premium tax credits (EPTCs) set to expire at the end of 2025 H.R.4371/S.2439 - Resident Physician Shortage Reduction Act of 2025 Issue: Support increased Medicare funding for graduate medical education (GME). Draft Bipartisan Senate Medicare GME Expansion proposal Issue: Support increased Medicare funding for graduate medical education (GME). Oppose duplicative teaching health system and hospital reporting and policies that increase regulatory burden. H.R.2314/S.2715 - Fair Access in Residency Act Issue: Oppose legislative interference in residency training program requirements and policies requiring the Medicare program to consider specific physician licensing exams for residency program applications. H.R.1153 - Rural Physician Workforce Production Act Issue: Oppose legislation redesigning Medicare graduate medical education (GME) payment formulas that reduce current Direct Graduate Medical Education (DGME) and Indirect Medical Education (IME) payments to teaching hospitals. Issue: Educate Congress on teaching health system and hospital graduate medical education (GME) data collection practices and concerns related to duplicative reporting requirements. H.R.3178/S.2600 - Save Healthcare Workers Act Issue: Support legislation providing protection for health care workers by creating a criminal offense for knowingly assaulting or intimidating hospital workers and providing grants to reduce violence in hospitals. Issue: Oppose legislation that pays for workforce investments and mitigation of Medicaid Disproportionate Share Hospital (DSH) program cuts paid for by cuts to hospital outpatient departments. Issue: Support legislation that ensures the move to value-based care. Issue: Educate Congress about the likely impact of legislation that would alter the distribution of Medicare-supported graduate medical education (GME) slots from the Consolidated Appropriations Act (CAA), 2021 and 2023. Issue: Educate Congress on status of Centers for Medicare and Medicaid Services (CMS) distribution of the 1,000 new graduate medical education (GME) slots authorized by the Consolidated Appropriations Act (CAA), 2021 (P.L.116-260). Support CMS changing its distribution methodology to end the practice of super prioritization. Issue: CAA, 2021 Sec. 131 extension and RTP thresholds Issue: Support Medicare graduate medical education (GME) per resident amount and cap-setting technical corrections and administrative relief. Issues: Support lifting cap on number of residents Medicare will count when determining teaching hospitals' Medicare Direct Graduate Medical Education (DGME) and Indirect Medical Education (IME) payments. Issue: Oppose reduction of Medicare Direct Graduate Medical Education (DGME) and Indirect Medical Education (IME) payments. Issue: Oppose the redesign of Medicare Indirect Medical Education (IME) financing and redistribution. Issue: Oppose establishing nationality-based restrictions on medical residencies supported by Medicare. Issue: Support creation of new Medicare outpatient Indirect Medical Education (IME) payment in addition to existing Medicare IME payment inpatient methodology. Oppose policies to create budget neutral IME payments for outpatient services. Issue: Support efforts to reform the Medicare physician fee schedule. H.R.879 - Medicare Patient Access and Practice Stabilization Act of 2025 H.R.9693 - Patients First Act of 2026 H.R.8163 - Provider Reimbursement Stability Act of 2026 Issue: Support Medicare Physician Fee Schedule (PFS) reform. P.L.119-4 - Full-Year Continuing Appropriations and Extensions Act, 2025 P.L.118-158 - American Relief Act 2025 Issues: Oppose reduction in Medicare hospital outpatient department reimbursement for drug administration and other services. Oppose site-neutral expansion to excepted off-campus provider-based departments (PBDs). Oppose creation of National Provider Number/unique identifier for off-campus hospital outpatient departments. Oppose Medicare hospital, and provider cuts. Support mitigation of Medicare Physician Fee Schedule (PFS) cuts. Support delaying or eliminating scheduled cuts to the Medicaid disproportionate share hospital (DSH) program. Support extension of alternative payment model (APM) bonus. Support allowing hospitals to count costs and reimbursements for Medicaid patients with third-party coverage towards their DSH cap. Support extensions of Acute Hospital at Home program waiver of 24/7 nursing requirement and Medicare telehealth waivers and efforts to expand patient access to telehealth. H.R.5582/S.2355 - Patients Deserve Price Tags Act H.R.9393 - Lower Costs, More Transparency Act of 2026 H.R.9390 - Prices on the Wall Act of 2026 Issue: Oppose efforts to increase administrative burden on hospitals through expanded reporting measures. Issue: Educate Congress on role of academic medicine as it relates to price transparency or disclosure initiatives. H.R.9504 - Tax Exempt Hospital Transparency Act Issue: Oppose efforts that increase duplicative and burdensome reporting requirements on tax exempt hospitals through expanded IRS reporting measures. H.R.3514/ S.1816 - Improving Seniors' Timely Access to Care Act of 2025 Issue: Support efforts to decrease the burden of prior authorization in Medicare Advantage plans Issue: Protect patients from delays in care by streamlining and standardizing prior authorization under the Medicare Advantage program and providing program oversight and transparency. Issue: Support elimination of scheduled reductions to the Medicaid disproportionate share hospital (DSH) program. H.R.8163 - Provider Reimbursement Stability Act of 2026 Issue: Support necessary changes and improvements to the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Issue: Support policies to close the Medicaid coverage gap and ensure access to coverage in non-expansion states, as well as financial incentives to help states maintain existing expansions. Support mandatory 12-month Medicaid coverage for post-partum individuals. Issue: Support waiving budget neutrality requirements associated with the E/M code changes or temporarily holding harmless physicians and other health care professionals. H.R.4313 - Hospital Inpatient Services Modernization Act Issue: Support extension of the Acute Hospital Care at Home program. Issue: Support extension of Medicare telehealth waivers and efforts to expand patient access to telehealth. Issue: Support policy to permanently remove the requirement for Medicare beneficiaries to be seen in-person every six months for telehealth visits for mental health services. Issue: Support legislation to eliminate the 190-day Lifetime Limit policy in the Medicare program. Issue: Support providing states with guidance to increase telehealth access in Medicaid and CHIP. Issue: Support increased access to behavioral health and substance use disorder treatment services under Medicare and Medicaid. Support the removal of regulatory barriers to telehealth-enabled mental health care, including electronic interprofessional consults (eConsults). S.2761/H.R.5269 - Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act Issue: Support legislation to modify Medicare payment rates for clinical diagnostic laboratory services to avoid statutory cuts to these payments. Issue: Support authorization of Medicare advance and accelerated payments in the wake of cyberattacks on providers. Issue: Support removing cost-sharing obligations from the chronic care management (CCM) code in Medicare. Issue: Oppose Department Homeland Security (DHS) proposed rule to expand public charge definition and educate Congress on potential impacts to health care providers.

Client expense: $431,446 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Health issues. Medicare/Medicaid issues. H.R.5269: RESULTS Act.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

FDA regulation, Laboratory Testing related issues H.R.8890, Clinical Laboratory Improvement Amendments (CLIA), Modernization generally H.R.5269/S.2761, Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act of 2025 (RESULTS Act), Entirety Possible Health policy package Monitor the following: Health workforce visa related issues H.R.3152/S.1546, Patent Eligibility Restoration Act of 2025, Laboratory technology related issues Possible Reconciliation, FY2027, Health related provisions Prescription drug costs, generally Public Law 117-328, Consolidated Appropriations Act, FY2023, Lab Infrastructure issues; and Diagnostic Lab Testing related issues Public Health reporting initiatives

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES

FDA regulation, Laboratory Testing related issues H.R.8890, Clinical Laboratory Improvement Amendments (CLIA), Modernization generally H.R.5269/S.2761, Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act of 2025 (RESULTS Act), Entirety Possible Health policy package Monitor the following: Health workforce visa related issues H.R.3152/S.1546, Patent Eligibility Restoration Act of 2025, Laboratory technology related issues Possible Reconciliation, FY2027, Health related provisions Prescription drug costs, generally Public Law 117-328, Consolidated Appropriations Act, FY2023, Lab Infrastructure issues; and Diagnostic Lab Testing related issues Public Health reporting initiatives

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES

Issues related to FDA, Medicare reimbursement, cancer screening, workforce shortages and artificial intelligence; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to reimbursement for diagnostic tests; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 7352/S. 4875 - PASTEUR Act of 2026; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act; Issues related to H.R. 6130/S. 3267 - ASAP Act.

Client expense: Not reported · Firm income: $70,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Medicare and Medicaid payment issues, alternative payment models, value-based healthcare/Medicare shared savings program; Health care workforce; Health care pricing transparency; Site Neutral; 340B Program and Drug Pricing; MA prior authorization (S. 1816 / H.R. 3514); Telehealth and digital health; Home health / Hospice; Rural health and Rural Hospital Support Act (S. 335); Graduate medical education; Artificial intelligence; The Affordable Care Act; RESULTS Act (H.R. 5269 / S. 2761); Equitable Community Access to Pharmacist Services (ECAPS) Act (H.R. 3164 / S. 2426); 340B PATIENTS Act (H.R. 4581 / S. 2372); CONNECT for Health Act (H.R. 4206 / S. 1261); H.R. 1708 / S. 1087 Rebuild America's Healthcare Schools Act of 2025; Medicare Physician Reimbursement/MACRA.

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough

Client expense: $90,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period.

Client expense: $90,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues impacting diagnostics, including oversight of laboratory-developed testing and reimbursement; Reforming and Enhancing Sustainable Updates to Laboratory Services (RESULTS) Act (H.R. 5269/S. 2761) and Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act (RESULTS) Act (H.R. 5259)

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Congressional outreach and monitoring regarding the following: -H.R. 3178/S.1600, Save Healthcare Workers Act. -H.R. 9504, Tax Exempt Hospital Transparency Act. -H.R. 9599, SECURE 340B Act. -H.R. 7961, H-1Bs for Physicians and the Healthcare Workforce Act. -H.R. 5269/S. 2761, RESULTS ACT. -S.4994, ONSHORE Manufacturing Act. -340B policy issues. -Site Neutral Payment Proposals. -Healthcare and hospital workforce budget and appropriations, generally. -Medicare and Medicaid reimbursements.

Client expense: $30,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Congressional outreach and monitoring regarding the following: -H.R. 3178/S.1600, Save Healthcare Workers Act. -H.R. 9504, Tax Exempt Hospital Transparency Act. -H.R. 9599, SECURE 340B Act. -H.R. 7961, H-1Bs for Physicians and the Healthcare Workforce Act. -H.R. 5269/S. 2761, RESULTS ACT. -S.4994, ONSHORE Manufacturing Act. -340B policy issues. -Site Neutral Payment Proposals. -Healthcare and hospital workforce budget and appropriations, generally. -Medicare and Medicaid reimbursements.

Client expense: $30,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R.1, One Big Beautiful Bill Act H.R. 3164/S. 2426, Main Street Pharmacy Access Act H.R. 3514/S. 1816, Improving Seniors Timely Access to Care Act H.R. 4093/S. 3848, Apples to Apples Comparison Act H.R. 4731/S. 2439, Resident Physician Shortage Reduction Act H.R. 5269/S. 2761, Reforming and Enhancing Sustainable Updates to Laboratory Services Act H.R. 5347, Health care Efficiency Through Flexibility Act U.S Department of Health and Human Services, Centers for Medicare & Medicaid Services Medicaid Program; Community Engagement Requirement for Certain Individuals Interim Final Rule with Comment Period (CMS-2454-IFC) U.S Department of Health and Human Services, Centers for Medicare & Medicaid Services Medicare and Medicaid Programs; CY 2027 Payment Policies under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program (CMS-1848-P)

Client expense: $150,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Ensuring Patient Access to Critical Breakthrough Products Act; HR 5269: Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES

Ensuring Patient Access to Critical Breakthrough Products Act; HR 5269: Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES

Issues related to reimbursement and coverage for clinical laboratory services, including the Medicare clinical laboratory fee schedule; implementation of the Protecting Access to Medicare Act (P.L. 113-93) and Consolidated Appropriations Act, 2026 (P.L. 119-75); RESULTS Act (H.R. 5269/S. 2761); laboratory coding, pricing, coverage, and payment; Improving Seniors' Timely Access to Care Act (H.R. 3514/S. 1816); Prior Authorization Accountability Act (H.R. 9396); program integrity initiatives.

Client expense: $850,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Issues related to reimbursement and coverage for clinical laboratory services, including the Medicare clinical laboratory fee schedule; implementation of the Protecting Access to Medicare Act (P.L. 113-93) and the Consolidated Appropriations Act, 2026 (P.L. 119-75); RESULTS Act (H.R. 5269/S. 2761); diagnostic regulatory reform; Enhancing CLIA Act (H.R. 8990); laboratory services as Essential Health Benefits; Patients Deserve Price Tags Act (H.R. 5582/S. 2355); Lower Costs, More Transparency Act (H.R. 9393); Health Care Price Certainty for All Americans Act (H.R. 9645); Prices on the Wall Act of 2026 (H.R. 9390).

Client expense: $850,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Issues related to reimbursement and coverage for clinical laboratory services, including the Medicare clinical laboratory fee schedule; implementation of the Protecting Access to Medicare Act (P.L. 113-93) and the Consolidated Appropriations Act, 2026 (P.L. 119-75); RESULTS Act (H.R. 5269/S. 2761); diagnostic regulatory reform; Enhancing CLIA Act (H.R. 8990); artificial intelligence in laboratory services; Timely Access to Coverage Decisions Act (H.R. 8500); laboratory services as Essential Health Benefits; laboratory coding, pricing, coverage, and payment.

Client expense: $850,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

General discussions related to clinical trials infrastructure and government labs, and related matters. General discussions regarding diagnostic reimbursement policies. General discussions regarding domestic pharmaceutical manufacturing. H.R. 5269/S. 2761: Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act of 2025 - all provisions of the bill. H.R. 5343/S. 1717: Ensuring Patient Access to Critical Breakthrough Products Act - all provisions of the bill. H.R. 9061: Preeclampsia Risk Evaluation and Evidence-based Management through Personalized Testing (PREEMPT) Act - all provisions of the bill.

Client expense: $550,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, White House Office

Senate Amendments to H.R. 7148 - Consolidated Appropriations Act, 2026 FY 2026 Appropriations Student VISA issues Price Tags / Transparency Legislation CDC funding NIH Funding Issues relating to surprise medical bills Advocating for relief from cuts to evaluation and management codes within Medicare Issues relating to site-neutral payments Issue relating to artificial intelligence Issues relating to Medicare coverage pathways Researching Long Covid Issues relating to the Clinical Laboratory Fee Schedule Issues relating to forensic pathologist loan repayment Funding for the CDC AMD program Funding for lab test harmonization Issues surrounding Health Data Privacy Medicare payment reform Challenges facing independent medicine PTAC Reform Issues relating to the local coverage determination process Issues relating to GME Issues relating to laboratory accreditation procedures of IVF centers Issues relating to site neutral payment reform Issues relating to Medicaid funding S. 2761 and H.R. 5269, the RESULTS Act Issues related to cancer Issues related to the Medicare Access and CHIP Reauthorization Act of 2015 2027 Proposed Physician Fee Schedule rule: Surgical pathology codes DHS final rule re: 100k H1-B visa Issues relating to the funding of national cancer registries

Client expense: $203,130 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R.5269/S.2761 - RESULTS Act Calendar Year 2027 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Proposed Rule (CMS-1850-P) CY 2027 Payment Policies under the Medicare Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies (CMS-1848-P)

Client expense: Not reported · Firm income: $70,500

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

No Bill No. - Physician payment reform No Bill No. - Value based care No Bill No. - Kids Access to Primary Care Act No Bill No. - Medicaid Primary Care Improvement Act No Bill No. - Alleviating Barriers for Caregivers (ABC) Act No Bill No. - MA Prompt Pay No Bill No. - CY2027 Medicare Physician Fee Schedule (H.R. 879) - Medicare Patient Access and Practice Stabilization Act (H.R. 1510) - Due Process Continuity of Care Act (S. 891) - Bipartisan Health Care Act (H.R. 1735/S. 779) - EARLY Minds Act (H.R. 786) - Reserving Patient Access to Accountable Care Act (S.2671/H.R. 5269) - RESULTS Act (2. 2749) - Medicare Sequester Exemption Bill (H.R. 483) - Health Care Efficiency Through Flexibility Act (H.R. 6160) - Strengthening Medicare for Patients and Providers Act (H.R. 6210) - Senior Savings Protection Act (S. 3300) - Access to New Community Health Opportunities and Recovery (ANCHOR) Act (S. 3522) - No Red Tape for Addiction Treatment Act (H.R. 8735/ S. 4384) - Medicare Advantage Improvements Act (H.R. 8390) - National Food as Medicine Program Act of 2026 (H.R. 8425) - Strengthening the Vaccines for Children Program Act of 2026 (H.R. 9693) - Patients First Act (S. 5296) - Pay PCPs Act

Client expense: $499,510 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

* On April 10, ADLM joined with other healthcare entities in endorsing H.R.8500, the Timely Access to Coverage Decisions Act, which would create a more transparent Medicare process for making coverage decisions. On July 20th and September 24th, ADLM initiated grassroots campaigns in support of H.R.5269 & S.2761, the RESULTS Act, which would revise the Medicare Clinical Laboratory Fee Schedule.

Client expense: $80,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, H.R. 9393, the Lower Costs, More Transparency Act, and H.R. 9645, the Health Care Price Certainty for All Americans Act, provisions relating to lab test price transparency; H.R. 9117, the Clear Healthcare Expense Cost Knowledge (CHECK) Act, provisions relating to administrative service provider price transparency and itemized patient billing; S. 3097, the Health Information Privacy Reform Act, provision relating to privacy of health data; H.R. 8500, the Timely Access to Coverage Decisions Act, provisions relating to establishment of standards for Medicare local coverage decisions; H.R. 8890, the Enhancing Clinical Laboratory Innovation and Access (Enhancing CLIA) Act, provisions relating to oversight of laboratory-developed tests; H.R. 6130/S. 3267, the Alzheimers Screening and Prevention (ASAP) Act, provisions relating to Medicare coverage of blood-based dementia screening tests; H.R. 5444, the Medical Laboratory Personnel Shortage Relief Act, provisions relating to amending the Public Health Service Act to address the shortage of medical laboratory personnel; Federal policy relating to prior authorization and oversight of laboratory benefit managers; Federal policy relating to access to mandatory code sets for administrative transactions; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.

Client expense: $250,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Medicare Clinical Laboratory Fee Schedule, The RESULTS Act (H.R.5269/S.2761)

Client expense: Not reported · Firm income: $70,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Physician Fee Schedule Provider Relief HR 879 Medicare Patient Access and Practice Stabilization Act Telehealth extension HR 5269 The RESULTS Act S.2761 The RESULTS Act H.R.2477 The PURE Act S.1168 The PURE Act

Client expense: $81,111 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE